ALTIMMUNE Aktie

>ALTIMMUNE Aktienkurs

3.004 EUR -1.1% (Tradegate)

Ask: 3.029 EUR / 6700 Stück

Bid: 3.004 EUR / 6700 Stück

Tagesumsatz: 30545 Stück

Realtime Kurs von 8 bis 22 Uhr!

ALTIMMUNE Aktie über LYNX handeln

Intraday

1 Jahr

>ALTIMMUNE Performance

1 Woche: -4,6%

1 Monat: -15,9%

3 Monate: -41,0%

6 Monate: -50,7%

1 Jahr: -51,7%

laufendes Jahr: -58,8%

>ALTIMMUNE Aktie

Name:

ALTIMMUNE INC. DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US02155H2004 / A2N5Z6

Symbol/ Ticker:

3G0 (Frankfurt) / ALT (NASDAQ)

Kürzel:

FRA:3G0, ETR:3G0, 3G0:GR, NASDAQ:ALT

Index:

Webseite:

https://altimmune.com/

Profil:

Altimmune, Inc. is a biopharmaceutical company eng..
>Volltext..

Marktkapitalisierung:

266.66 Mio. EUR

Unternehmenswert:

125.98 Mio. EUR

Umsatz:

0.02 Mio. EUR

EBITDA:

-80.43 Mio. EUR

Nettogewinn:

-74.89 Mio. EUR

Gewinn je Aktie:

-1.01 EUR

Schulden:

13.53 Mio. EUR

Liquide Mittel:

156.32 Mio. EUR

Operativer Cashflow:

-69.88 Mio. EUR

Bargeldquote:

19.86

Umsatzwachstum:

-95.55%

Gewinnwachstum:

21.27%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Div. Historie:

20.01.17 - 241212.3€

Insiderhandel:

Suchwörter:

ALTIMMUNE

Letzte Datenerhebung:

24.08.25

>ALTIMMUNE Kennzahlen

Aktien/ Unternehmen:

Aktien: 88.26 Mio. St.

Frei handelbar: 98.95%

Leerverk. Aktien: 36.22%

Rückkaufquote: -26.6%

Mitarbeiter: 59

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 422.21%

Bewertung:

KGV: -

KGV lG: -

KUV: 14420.71

KBV: 1.88

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -545%

Gewinnmarge: -438730%

Operative Marge: -471850%

Managementeffizenz:

Gesamtkaprendite: -48.25%

Eigenkaprendite: -55.91%

>ALTIMMUNE Peer Group

Es sind 601 Aktien bekannt.

>ALTIMMUNE Chart & Kurs - NASDAQ

>ALTIMMUNE News

22.08.25 - 14:51	October 6, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ALT (PR Newswire)
	NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely......

21.08.25 - 17:09	INVESTOR REMINDER: Berger Montague Notifies Altimmune, Inc. (NASDAQ: ALT) Investors of a Class Action Lawsuit and Deadline (PR Newswire)
	PHILADELPHIA, Aug. 21, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of......

21.08.25 - 17:06	SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Altimmune between August 10, 2023 and June 25, 2025......

21.08.25 - 14:48	Contact The Gross Law Firm by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc.(ALT) (PR Newswire)
	NEW YORK, Aug. 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.......

20.08.25 - 23:42	ALT STOCK: Robbins LLP Reminds ALT Stockholders of the Opportunity to Lead the Class Action Lawsuit Against Altimmune, Inc. (PR Newswire)
	SAN DIEGO, Aug. 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023 and June 25, 2025. Altimmune is a clinical stage......

19.08.25 - 15:18	Altimmune wins FDA fast track status for alcohol use disorder therapy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.08.25 - 13:33	Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire EN)
	Pemvidutide is the only drug currently granted Fast Track Designation in AUD...

19.08.25 - 00:45	Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders to Contact the Firm for Information About Their Rights (PR Newswire)
	NEW YORK, Aug. 18, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the "Class Period"). If you wish to......

18.08.25 - 14:48	The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT (PR Newswire)
	NEW YORK, Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.......

15.08.25 - 18:09	Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT) (PR Newswire)
	PHILADELPHIA, Aug. 15, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") following the filing of a securities class action lawsuit filed on behalf of investors......

15.08.25 - 17:51	Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to......

15.08.25 - 15:18	Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT (PR Newswire)
	NEW YORK, Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely......

15.08.25 - 03:36	ALT Stock News: Altimmune, Inc. Stockholder Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Altimmune, Inc. (PR Newswire)
	SAN DIEGO, Aug. 14, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023 and June 25, 2025. Altimmune is a clinical stage......

14.08.25 - 14:48	The Gross Law Firm Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT (PR Newswire)
	NEW YORK, Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.......

13.08.25 - 23:33	Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders to Contact the Firm for Information About Their Rights (PR Newswire)
	NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the "Class Period"). If you wish to......

12.08.25 - 19:57	Berger Montague PC Investigating Claims on Behalf of Altimmune, Inc. (NASDAQ: ALT) Investors After Class Action Filing (PR Newswire)
	PHILADELPHIA, Aug. 12, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of......

12.08.25 - 19:27	Altimmune stock rises on promising Q2 report (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.25 - 13:06	Altimmune GAAP EPS of -$0.27 beats by $0.04 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.08.25 - 16:33	Altimmune Q2 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.08.25 - 16:03	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT (PR Newswire)
	NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Unzufriedenheit ist die erste Stufe zum Fortschritt für den einzelnen wie für die Nation. - Oscar Wilde

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram